| Document |
Document Title |
|
WO/2024/068159A1 |
This application relates generally to the field of synthesis, formulations and perivascular treatment methods involving cyclic ester derivatives of everolimus.
|
|
WO/2024/054115A1 |
The disclosure relates to organosulfur compounds and compositions comprising same. In particular, the disclosure relates to Bis(4-fluorophenyl) disulfide, Bis(4- chlorophenyl) disulfide, Bis(4-chlorophenyl) thiosulfinate, Bis(4-fluorophe...
|
|
WO/2024/038088A1 |
The present invention provides an aqueous liquid composition comprising a conjugate of hyaluronan and a pharmaceutically active compound, and a sugar or sugar alcohol, wherein the concentration of the sugar or sugar alcohol in the compos...
|
|
WO/2024/020564A1 |
The present invention provides monospecific and multispecific antigen-binding molecules and compositions thereof. The invention also features methods of treating a disease or disorder, such as cancer, methods of inhibiting tumor growth, ...
|
|
WO/2023/231964A1 |
Provided are a use of a tetrahydronaphthyridine derivative in the preparation of a medicine for preventing and treating gastrointestinal tract injury-related diseases or inhibiting gastrointestinal protein kinase; the compound achieves a...
|
|
WO/2023/181563A1 |
Provided is an anti-adhesive material containing particles, in which the particles comprise a crosslinked product of a gelatin mixture composed of a first gelatin and a second gelatin having such a structure that a hydrocarbon group is i...
|
|
WO/2023/161662A1 |
A composition for the use in peritoneal dialysis (PD) is hereby provided, the composition comprising a biologically compatible solvent, an osmotic agent and a complement inhibitor. Methods of manufacturing and of use of the composition a...
|
|
WO/2023/150338A1 |
A method for treating cancer. The method comprises treating a patient having a cancerous tumor with a gene inhibitor pre-operatively to inhibit upregulation of a particular gene, surgically removing the cancerous tumor, treating the pati...
|
|
WO/2023/096330A1 |
The present invention relates to a composition which is for promoting angiogenesis and comprises thymosin β-4 fusion proteins. The thymosin β-4 fusion proteins according to an aspect of the present invention can very effectively pass t...
|
|
WO/2023/081681A1 |
Disclosed herein are nitric oxide donors and methods of use thereof.
|
|
WO/2022/104128A9 |
This document provides fibrin hydrogels and methods and materials for making and using fibrin hydrogels. For example, this document provides fibrin hydrogels containing trypan blue (TB), Evans blue (EB), and/or one or more isomers thereo...
|
|
WO/2023/038522A1 |
The disclosure relates to organosulfur containing compositions, in particular Di-n-butyl thiosulfinate, Di-methyl thiosulfonate, Di -phenyl thiosulfonate, Bis (p-tolyl) thiosulfinate, Di-isopropyl thiosulfinate, Di-benzyl thiosulfinate, ...
|
|
WO/2023/034898A1 |
This invention relates to methods and compositions for inhibiting fibrosis and the formation of scars, e.g., as a result of corneal wounds, by administering NBL1 to a subject. The invention further relates to methods and compositions for...
|
|
WO/2023/026043A1 |
The present invention relates to nutritional compositions for maintaining and enhancing one carbon (1C) metabolism. The compositions are useful for maintaining general body health, reducing physiological consequences of metabolic stress,...
|
|
WO/2022/258734A1 |
The present invention relates to a sterilized, gel-forming multicomponent composition comprising a component containing at least one crosslinkable polymer and a component containing at least one crosslinking agent. The present invention ...
|
|
WO/2022/242533A1 |
A gel composition for improving the efficiency of calculus lithotripsy surgery of the urinary system and assisting in the removal of stone fragments in a kidney collection system. The gel composition comprises component A and component B...
|
|
WO/2022/234489A1 |
Described herein are methods and compositions for treating and preventing peripheral nerve injury, and more particularly hypoxia-associated tissue damage such as peripheral nerve fibrosis. The methods described include the administration...
|
|
WO/2022/206882A1 |
The present invention relates to an in-situ drug-loaded hydrogel, a preparation method therefor and the use thereof. A method for preparing a multi-arm polyethylene glycol derivative complex. The method comprises pre-freezing a multi-arm...
|
|
WO/2022/174321A1 |
This disclosure provides a hyaluronic acid (HA) bead, a filler comprising same and a process for preparing the HA beads. The process includes combining an HA compound with sodium hydroxide, forming an HA solution, and injecting the HA so...
|
|
WO/2022/145885A1 |
The present invention relates to a method for producing a biomaterial for tissue repair, which significantly reduces the amount of a crosslinking agent used by means of a crosslinking reaction through a differentiated mixing and transfor...
|
|
WO/2022/140316A1 |
The present invention provides compounds useful for the treatment of narcolepsy or cataplexy in a subject in need thereof. Related pharmaceutical compositions and methods are also provided herein.
|
|
WO/2022/138626A1 |
A compound (Z) represented by general formula (1) or general formula (2). [In general formula (1), and general formula (2), each X independently represents a carboxy group, a carboxylate group, or a monovalent group represented by genera...
|
|
WO/2022/126259A1 |
The present disclosure relates generally to treatment of peritoneal, pleural, and pericardium adhesions.
|
|
WO/2022/103768A1 |
The present disclosure provides compositions and methods for inhibition of tissue adhesion. According to specific aspects, implantable anti-adhesion zwitterionic compositions which include: an aqueous liquid; and a zwitterionic polymer a...
|
|
WO/2022/084478A1 |
Methods and products for surgery, in particular products and methods for preventing surgical adhesion, for stopping or reducing bleeding in an open surgical wound, and for treating surgical wounds. preventing surgical adhesion between su...
|
|
WO/2022/079315A1 |
A parapharmaceutical or pharmaceutical composition administrable to living beings, in particular to human beings, comprising at least one endoribonuclease enzyme chosen from the EC 3.1.30 and EC 3.1.31 classes, preferably in a content of...
|
|
WO/2022/074236A2 |
The invention provides methods and means for the inhibition or neutralisation of death receptor/death ligand members of the tumour necrosis factor superfamil and TNF receptor superfamilies and/or the Toll-like receptor family, and/or NOD...
|
|
WO/2022/067042A1 |
A cryoprotective composition configured to be applied during cryotreatment of a patient includes at least one biodegradable and/or bioerodible fluid agent and at least one non-toxic cryoprotectant agent. A therapeutically effective amoun...
|
|
WO/2022/055559A1 |
A method is disclosed for treating a fistula in a subject, such as, but not limited to, an anal fistula. In some embodiments, the method includes administering locally to the fistula in the subject an effective amount of a composition co...
|
|
WO/2022/052631A1 |
Provided are an application of a citrate metal salt in endodontic treatment, and a formulation obtained by preparation; said citrate metal salt is used for removing a tarnished layer, and the citrate metal salt is lithium citrate, sodium...
|
|
WO/2022/050695A1 |
The present invention relates to a hydrogel patch comprising: a hydrogel patch including a biocompatible polymer modified with a phenol group; and an extracellular matrix supported on the hydrogel patch.
|
|
WO/2022/027970A1 |
Provided are a formulation for a submucosal injection and the use thereof. The formulation comprises a divalent cation and an oligosaccharide. The oligosaccharide is obtained by exposing a polysaccharide powder to radiation, thermal ener...
|
|
WO/2021/259423A1 |
The invention relates to the use of at least one inhibitory structural analog or inhibitory functional analog of a coenzyme (such as thiamine for example) of an enzyme group, the enzyme members of which catalyze anabolic and/or catabolic...
|
|
WO/2021/252945A1 |
Presented are methods of assessing a deficit in DNA damage repair capability in cancer cells. Cancer cells having this DNA damage repair phenotype have increased susceptibility to certain treatments, including genotoxic treatments, treat...
|
|
WO/2021/243432A1 |
The present invention refers to pharmaceutical compositions and to a process for producing them, comprising delphinidin alone or in combination with brilliant blue and/or trypan blue for staining biological material and improving the ide...
|
|
WO/2021/198785A1 |
Devices, systems, and methods for combinatorial treatment of a condition with an implantable damping device and biologic therapeutic agent are disclosed herein. Methods for treating one or more effects of the condition, such as a neurolo...
|
|
WO/2021/175605A1 |
The present invention relates to compositions comprising gases, particularly oxygen (O2) in an amount of from about 91% to about 99% by volume, and carbon dioxide (CO2) in an amount of from about 1% to about 9% by volume, based upon the ...
|
|
WO/2021/177894A1 |
The present invention relates, in general terms, to methods of reducing the formation of post-surgery tissue adhesion in a subject in need thereof by administering an adhesion barrier composition. The present invention also relates to me...
|
|
WO/2021/157619A1 |
The present invention provides: an agent which is for preventing or treating pancreatic leak and/or pancreatic fistula after abdominal surgery and contains a lipase inhibitor as an active ingredient; and a method which is for preventing ...
|
|
WO/2021/153635A1 |
The present invention provides a non-lamellar liquid crystal forming composition which is highly safe. The present invention relates to a non-lamellar liquid crystal forming composition that includes an amphipathic compound represented b...
|
|
WO/2021/118469A1 |
The present invention relates to the use of valproic acid for reducing post-operative scarring following a glaucoma surgery. In one embodiment, the glaucoma surgery is glaucoma filtering surgery, which comprises creating a subconjunctiva...
|
|
WO/2021/092670A1 |
The present invention relates to a fixed-rotor centrifuge (10) for producing an autologous platelet-rich fibrin matrix for non-transfusion therapeutic purposes and use in regenerative medicine. Said centrifuge (10) has a rotor (11) attac...
|
|
WO/2021/060336A1 |
Provided are a novel crosslinked alginic acid, a crosslinked alginic acid structure, etc., by performing a crosslinking reaction using alginic acid derivatives represented by formula (I) and formula (II). As a result, a novel crosslinked...
|
|
WO/2021/055636A1 |
A medication or combination of medications for the treatment of a disease involving the sinuses is incorporated into a sterile medical gel. The viscosity of the gel or the adhesion of the gel to the patient's sinus cavity allows the gel ...
|
|
WO/2021/051778A1 |
A disulfide bond-linked hyaluronic acid gel for preventing tissue adhesion after abdominal or pelvic cavity surgery and a preparation method therefor. The content of the disulfide bond-linked hyaluronic acid of the disulfide bond-linked ...
|
|
WO/2021/048595A1 |
The disclosure relates to methods of preventing an human virus-associated disorder, in particular EBV-associated disorder, as well as to a method of controlling EBV load in a subject, in particular in a subject being at risk of developin...
|
|
WO/2021/013714A1 |
The invention relates to a composition comprising Mesna for use in a method of surgery. The invention also relates to a method for producing a composition comprising Mesna for use in a method of surgery, to a kit for obtaining a composit...
|
|
WO/2021/013713A1 |
The invention relates to a composition comprising Mesna, wherein the composition further comprises one or more dyes. The invention also relates to said composition for use in a method of surgery, a kit comprising Mesna and a method for v...
|
|
WO/2020/237323A1 |
Compositions and methods for the preparation of a subject for fecal microbiota transplantation, in particular for the removal of biofilm material from the colon of a subject, are provided. The provided compositions contain soaps, such as...
|
|
WO/2020/232540A1 |
A method of reducing or limiting tissue adhesion comprises contacting the tissue with an effective amount of a hydrogel composition comprising: 2% to 6% by weight hyaluronan, and 3% to 18% by weight methylcellulose, wherein the combined ...
|
